Hickory Asset Management Inc. Invests $941,000 in IQVIA Holdings Inc. (NYSE:IQV)

Hickory Asset Management Inc. purchased a new position in shares of IQVIA Holdings Inc. (NYSE:IQV) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 4,787 shares of the medical research company’s stock, valued at approximately $941,000.

Other institutional investors also recently added to or reduced their stakes in the company. FMR LLC grew its stake in shares of IQVIA by 38.7% in the 3rd quarter. FMR LLC now owns 2,887,342 shares of the medical research company’s stock valued at $684,213,000 after purchasing an additional 804,963 shares during the last quarter. JPMorgan Chase & Co. boosted its position in IQVIA by 46.2% during the third quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company’s stock worth $437,378,000 after purchasing an additional 583,396 shares in the last quarter. Impax Asset Management Group plc boosted its position in IQVIA by 9.7% during the third quarter. Impax Asset Management Group plc now owns 1,793,010 shares of the medical research company’s stock worth $423,885,000 after purchasing an additional 157,809 shares in the last quarter. Nordea Investment Management AB boosted its position in IQVIA by 47.4% during the fourth quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company’s stock worth $277,908,000 after purchasing an additional 452,029 shares in the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in shares of IQVIA by 3.4% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,226,083 shares of the medical research company’s stock worth $290,545,000 after acquiring an additional 39,772 shares during the last quarter. Institutional investors and hedge funds own 89.62% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts recently commented on IQV shares. Deutsche Bank Aktiengesellschaft dropped their target price on IQVIA from $270.00 to $265.00 and set a “buy” rating for the company in a research note on Friday, November 1st. TD Cowen lowered their price target on IQVIA from $270.00 to $255.00 and set a “buy” rating for the company in a research report on Friday, November 1st. Truist Financial reissued a “buy” rating and set a $263.00 price target (up previously from $261.00) on shares of IQVIA in a research report on Monday, February 10th. BTIG Research downgraded IQVIA from a “buy” rating to a “neutral” rating in a research report on Monday, February 3rd. Finally, The Goldman Sachs Group decreased their target price on IQVIA from $280.00 to $250.00 and set a “buy” rating for the company in a research report on Friday, November 1st. Five analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $251.67.

IQVIA Trading Down 1.2 %

Shares of NYSE IQV opened at $193.65 on Friday. The company has a quick ratio of 0.81, a current ratio of 0.84 and a debt-to-equity ratio of 2.12. The stock’s 50 day moving average price is $200.59 and its two-hundred day moving average price is $218.51. The stock has a market capitalization of $35.15 billion, a P/E ratio of 25.82, a PEG ratio of 2.25 and a beta of 1.48. IQVIA Holdings Inc. has a 52-week low of $187.62 and a 52-week high of $261.73.

IQVIA (NYSE:IQV) last announced its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. On average, analysts anticipate that IQVIA Holdings Inc. will post 10.81 earnings per share for the current fiscal year.

Insider Activity at IQVIA

In other news, Director John G. Danhakl purchased 1,275 shares of the firm’s stock in a transaction on Tuesday, December 3rd. The stock was purchased at an average cost of $200.58 per share, with a total value of $255,739.50. Following the purchase, the director now owns 1,275 shares in the company, valued at $255,739.50. This trade represents a ∞ increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 1.60% of the stock is owned by insiders.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.